

Twist Alliance Pan-Cancer Methylation Panel to enter global cancer market

12 October 2021 | News

A strategic collaboration between AnchorDx and Twist Bioscience for pan-cancer liquid biopsy



The Twist Alliance Pan-Cancer Methylation Panel (Pan-Cancer Panel), a solution for pan-cancer study including DNA methylation library preparation and targeted enrichment for next-generation sequencing (NGS), has been launched globally. The Pan-Cancer Panel was developed over a two-year period by China-based startup AnchorDx in collaboration with Twist Bioscience, another startup based in the US.

The Pan-Cancer Panel, coupled the DNA methylation markers that were discovered, curated and validated by AnchorDx from many large-scale clinical studies, with the superior panel design, high-quality DNA synthesis platform and the strict quality control process developed by Twist Bioscience, ensures robust and high-performance output for large-scale screening of patient samples.

The panel covers 47 disease entities from The Cancer Genome Atlas (TCGA) and 31 cancer types, such as lung, breast and colorectal cancers, each is represented by ~1000 informative genomic regions.

"We hope to make our due contribution to the global cancer screening efforts, and look forward to future collaborations with either academics or industries to develop more impactful clinical products." said Dr. Jian-Bing Fan, CEO and Founder of AnchorDx.